PRIMO 2022 | Updates in PARP inhibition for ovarian cancer

Don Dizon, FACP, FASCO, MD, Brown University, Providence, RI, describes developments in using PARP inhibitors for ovarian cancer, especially in patients with mutations in DNA damage repair genes such as BRCA. The discovery of certain genes that predict sensitivity to PARP inhibitors such as RAD51C or RAD51D will help identity patients who will benefit the most. Retreatment with PARP inhibitors in the second or third line setting following progression from maintenance therapy has also proven to be efficacious and further research is being conducted to assess novel combinations such as PARP inhibitors with immunotherapy or antiangiogenic drugs. This interview took place at the 7th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting (PRIMO 2022).